Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Inflammatory Bowel Disease II: Ulcerative Colitis01:20

Inflammatory Bowel Disease II: Ulcerative Colitis

Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Recurrence of Crohn's disease in end ileostomies.

Inflammatory bowel diseases·2013
Same author

The Appendix and IBD: Appendectomy Does Not Protect Against Ulcerative Colitis.

Inflammatory bowel diseases·2013
Same author

Crohn's disease: to lump or to split?

Inflammatory bowel diseases·2013
Same author

Rarity of fistulas in Crohn's disease of the jejunum.

Inflammatory bowel diseases·2013
Same author

Review article: colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease.

Alimentary pharmacology & therapeutics·2011
Same author

Adenocarcinoma complicating restorative proctocolectomy for ulcerative colitis with mucosectomy performed by Cavitron Ultrasonic Surgical Aspirator.

Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland·2008

Related Experiment Video

Updated: Jul 15, 2026

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

Treatment responses in collagenous colitis.

L M Fiedler1, J George, D B Sachar

  • 1The Dr. Henry D. Janowitz Division of Gastroenterology, Department of Medicine, Mount Sinai School of Medicine of the City University of New York, New York, USA.

The American Journal of Gastroenterology
|March 31, 2001
PubMed
Summary

Collagenous colitis is treatable in most patients. Initial therapies include antidiarrheals and 5-aminosalicylic acid (5-ASA), with prednisone for refractory cases.

More Related Videos

Isolation of Lamina Propria Mononuclear Cells from Murine Colon Using Collagenase E
09:48

Isolation of Lamina Propria Mononuclear Cells from Murine Colon Using Collagenase E

Published on: September 26, 2019

Murine Model of Epicutaneously-Induced Immunomodulation
09:07

Murine Model of Epicutaneously-Induced Immunomodulation

Published on: June 24, 2025

Related Experiment Videos

Last Updated: Jul 15, 2026

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

Isolation of Lamina Propria Mononuclear Cells from Murine Colon Using Collagenase E
09:48

Isolation of Lamina Propria Mononuclear Cells from Murine Colon Using Collagenase E

Published on: September 26, 2019

Murine Model of Epicutaneously-Induced Immunomodulation
09:07

Murine Model of Epicutaneously-Induced Immunomodulation

Published on: June 24, 2025

Area of Science:

  • Gastroenterology
  • Colorectal Diseases
  • Immunology

Background:

  • Collagenous colitis (CC) is a rare colonic subepithelial disease.
  • Therapeutic outcomes for CC have not been systematically described.
  • This study analyzes treatment responses in a cohort of CC patients.

Purpose of the Study:

  • To systematically describe therapeutic outcomes in patients with collagenous colitis.
  • To evaluate the effectiveness of various treatment modalities for CC.

Main Methods:

  • Retrospective analysis of 26 patients diagnosed with collagenous colitis between 1991 and 1994.
  • Review of patient demographics, symptoms, therapies, and outcomes.
  • Defined outcomes: Complete Remission (CR), Partial Remission (PR), Failure, and Relapse.

Main Results:

  • 22 of 26 patients responded to therapy; one had spontaneous remission.
  • 12 patients maintained remission with 5-aminosalicylic acid (5-ASA) and/or antidiarrheals.
  • Six patients required prednisone for sustained remission; two failed all therapies.

Conclusions:

  • Collagenous colitis is a treatable condition in the majority of patients.
  • Recommended initial therapy: antidiarrheals, followed by 5-ASA.
  • Prednisone is indicated for refractory cases, with subsequent attempts to taper medication.